New Vaccine Export Record
Green Cross (President Huh Eun-cheol) made history in the Korean medicine industry by exporting over US$200 million worth of goods last year. The exports increased 40 percent from the previous year, which was also a record amount.
The exports of the vaccine field, including flu and chickenpox, grew around 60 percent compared to 2013 by recording US$60 million. It exported US$38 million of a flu vaccine through bidding with the Pan American Health Organization (PAHO) under WHO, which is one of the world's largest demand sources.
The sales of blood demarcation medicines such as albumin, which prevents shock from excessive bleeding, and IV-Globulin-SN, which treats immune deficiency, have increased in emerging markets including China, India, and the Middle East.
Also there have been increasing exports in the type of plant. The company won an order for a blood demarcation medicine plant in January 2013 from the Thailand Red Cross. This is the first time for a domestic medicine company to export biological medicine plants abroad.
Last month, Green Cross signed a memorandum of understanding with an Indonesian company to build an Indonesian Red Cross blood demarcation medicine plant with a 25 liter capacity.
Green Cross said, “This year, we plan to expand blood demarcation exports into new markets such as the Middle East and South America,” adding, “Amount of chickenpox and flu vaccine orders is expected to increase greatly, due to the expansion of Expanded Programme on Immunization of the Middle and South American countries.”